Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference

From Startup Magenta Therapeutics

Link to Full Article:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2018–
Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company
developing novel medicines to bring the curative power of bone marrow
transplant to more patients, today announced that the Company is
scheduled to present at the 2018 Wedbush PacGrow Healthcare Conference
on Tuesday, August 14th, at 9:10 a.m. ET.

A live webcast of the presentation can be accessed under “Events &
Presentations” in the Investors and Media section of the company’s
website at
A replay of the webcast will be archived on the Magenta website for 30
days following the presentation.

About Magenta TherapeuticsHeadquartered in Cambridge,
Mass., Magenta Therapeutics is a clinical-stage biotechnology company
developing therapeutics focused on critical areas of unmet need in the
field of bone marrow transplant for patients with autoimmune diseases,
blood cancers and genetic diseases. By creating a platform focused on
critical areas of unmet need, Magenta Therapeutics is pioneering an
integrated approach to extend the curative power of bone marrow
transplant to more patients by making the process more effective, safer
and easier.

Forward-Looking StatementThis press release may contain
forward-looking statements, including statements regarding Magenta’s
financing plans, clinical trials and product candidate development.
Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based on management’s current
beliefs, expectations and assumptions regarding the future of Magenta’s
business, future plans and strategies, development plans, clinical
results and other future conditions. Such statements are subject to
certain risks and uncertainties, including, but not limited to:
uncertainties related to the initiation and conduct of trials and
studies and other development requirements for Magenta’s product
candidates; the risk that any one or more of Magenta’s product
candidates will not be successfully developed and commercialized; the
risk that the results of preclinical studies or clinical trials will not
be predictive of future results in connection with future studies or
trials; risks related to Magenta’s ability to protect and maintain its
intellectual property position; and risks related to Magenta’s
relationships with third parties. Although Magenta’s forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Magenta. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Magenta’s
programs and operations are described in additional detail in its
registration statement on Form S-1 and in the company’s other filings
from time to time with the SEC. Any forward-looking statement made in
this press release speaks only as of the date on which it is made.
Magenta undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise.

View source version on
Source: Magenta Therapeutics

Magenta Therapeutics:Manisha Pai, 857-242-1155Vice
President, Communications & Investor

Please visit their site for more information: Magenta

All,Biotechnology,Healthcare News,Startup News
2018-08-08 20:36:50